{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:44:14Z","timestamp":1792424654682,"version":"4.5.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2011,5,16]],"date-time":"2011-05-16T00:00:00Z","timestamp":1305504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0019389","type":"journal-article","created":{"date-parts":[[2011,5,16]],"date-time":"2011-05-16T17:00:17Z","timestamp":1305565217000},"page":"e19389","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Zoledronic Acid Preserves Bone Structure and Increases Survival but Does Not Limit Tumour Incidence in a Prostate Cancer Bone Metastasis Model"],"prefix":"10.1371","volume":"6","author":[{"given":"Tzong-Tyng","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl A.","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,5,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.","volume":"12","author":"TA Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.juro.2008.04.140","article-title":"Histopathological assessment of prostate cancer bone osteoblastic metastases.","volume":"180","author":"MP Roudier","year":"2008","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.","volume":"98","author":"RN Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bone.2003.07.012","article-title":"In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells.","volume":"34","author":"N Rucci","year":"2004","journal-title":"Bone"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.","volume":"24","author":"WG Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/ijc.23602","article-title":"Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions.","volume":"123","author":"J Liao","year":"2008","journal-title":"Int J Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/0008-5472.CAN-08-3506","article-title":"Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.","volume":"69","author":"G Wang","year":"2009","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model.","volume":"10","author":"T Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1019905111666","article-title":"The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.","volume":"75","author":"T Michigami","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.","volume":"18","author":"PI Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0736-0266(02)00095-5","article-title":"Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone.","volume":"21","author":"Y Lee","year":"2003","journal-title":"J Orthop Res"},{"key":"ref12","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.","volume":"9","author":"E Corey","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1002\/pros.21010","article-title":"A novel model of bone-metastatic prostate cancer in immunocompetent mice.","author":"CA Power","year":"2009"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/10520299209110046","article-title":"Modified tetrachrome method for osteoid and defectively mineralized bone in paraffin sections.","volume":"67","author":"ZA Ralis","year":"1992","journal-title":"Biotech Histochem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.eururo.2007.02.033","article-title":"Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.","volume":"52","author":"M Lein","year":"2007","journal-title":"Eur Urol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.","volume":"13","author":"SP Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"Suppl 3","key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2005.09.002","article-title":"Anti-tumour activity of zoledronic acid.","volume":"31","author":"P Clezardin","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.","volume":"102","author":"F Dieli","year":"2003","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/sj.bjc.6604390","article-title":"Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.","volume":"98","author":"D Generali","year":"2008","journal-title":"Br J Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.pcan.4500815","article-title":"Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.","volume":"8","author":"JE Quinn","year":"2005","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/382448a0","article-title":"Increased bone formation in osteocalcin-deficient mice.","volume":"382","author":"P Ducy","year":"1996","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2407-6-15","article-title":"Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.","volume":"6","author":"KD Brubaker","year":"2006","journal-title":"BMC Cancer"},{"key":"ref23","article-title":"Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.","author":"HT Hatoum","year":"2010"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","article-title":"Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.","volume":"76","author":"F Saad","year":"2010","journal-title":"Urology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijrobp.2006.08.022","article-title":"Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment.","volume":"67","author":"V Vassiliou","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10585-007-9066-x","article-title":"A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate.","volume":"24","author":"V Vassiliou","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0360-3016(03)00525-X","article-title":"Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs.","volume":"57","author":"V Kouloulias","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.","volume":"20","author":"HD Menssen","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0019389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T10:23:06Z","timestamp":1540203786000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0019389"}},"subtitle":[],"editor":[{"given":"Wafik S.","family":"El-Deiry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,5,16]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,5,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0019389","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,16]]}}}